85 related articles for article (PubMed ID: 21505085)
41. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
42. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.
Yu H; Hendrikx JJ; Rottenberg S; Schellens JH; Beijnen JH; Huitema AD
AAPS J; 2016 Mar; 18(2):362-71. PubMed ID: 26603889
[TBL] [Abstract][Full Text] [Related]
43. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
44. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.
Hendrikx JJ; Lagas JS; Wagenaar E; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Br J Cancer; 2014 May; 110(11):2669-76. PubMed ID: 24781280
[TBL] [Abstract][Full Text] [Related]
45. Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models.
Marathe PH; Rodrigues AD
Methods Mol Biol; 2010; 596():385-403. PubMed ID: 19949933
[TBL] [Abstract][Full Text] [Related]
46. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
Oostendorp RL; Huitema A; Rosing H; Jansen RS; Ter Heine R; Keessen M; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jun; 15(12):4228-33. PubMed ID: 19509162
[TBL] [Abstract][Full Text] [Related]
47. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
[TBL] [Abstract][Full Text] [Related]
48. No relation between docetaxel administration route and high-grade diarrhea incidence.
Hendrikx JJMA; Stuurman FE; Song JY; de Weger VA; Lagas JS; Rosing H; Beijnen JH; Schinkel AH; Schellens JHM; Marchetti S
Pharmacol Res Perspect; 2020 Aug; 8(4):e00633. PubMed ID: 32725720
[TBL] [Abstract][Full Text] [Related]
49. Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.
Loos NHC; Bui V; de Jong DH; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38456955
[TBL] [Abstract][Full Text] [Related]
50. Multiple effects of magnesium isoglycyrrhizinate on the disposition of docetaxel in docetaxel-induced liver injury.
Qu B; Xing R; Wang H; Chen X; Ge Q; Peng D; Wang G
Xenobiotica; 2017 Apr; 47(4):290-296. PubMed ID: 27218144
[TBL] [Abstract][Full Text] [Related]
51. Clinical pharmacokinetics of docetaxel : recent developments.
Baker SD; Sparreboom A; Verweij J
Clin Pharmacokinet; 2006; 45(3):235-52. PubMed ID: 16509758
[TBL] [Abstract][Full Text] [Related]
52. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
Yu H; Janssen JM; Sawicki E; van Hasselt JGC; de Weger VA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR
J Clin Pharmacol; 2020 Mar; 60(3):340-350. PubMed ID: 31595980
[TBL] [Abstract][Full Text] [Related]
53. Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.
Loos WJ; Zamboni WC; Engels FK; de Bruijn P; Lam MH; de Wit R; Verweij J; Wiemer EA
J Pharm Biomed Anal; 2007 Oct; 45(2):288-94. PubMed ID: 17804188
[TBL] [Abstract][Full Text] [Related]
54. Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect.
Puisset F; Chatelut E; Sparreboom A; Delord JP; Berchery D; Lochon I; Lafont T; Roché H
Cancer Chemother Pharmacol; 2007 Jul; 60(2):305-8. PubMed ID: 17124593
[TBL] [Abstract][Full Text] [Related]
55. An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics.
Meille C; Iliadis A; Barbolosi D; Frances N; Freyer G
J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):619-33. PubMed ID: 19107581
[TBL] [Abstract][Full Text] [Related]
56. Role of cytochrome P450 phenotyping in cancer treatment.
Dees EC; Watkins PB
J Clin Oncol; 2005 Feb; 23(6):1053-5. PubMed ID: 15657406
[No Abstract] [Full Text] [Related]
57. Castration-dependent pharmacokinetics of docetaxel: do sex and/or ABCB1 polymorphism also matter?
Gligorov J; Fajac A; Bernaudin JF
J Clin Oncol; 2011 May; 29(15):e454-5; author reply e456-7. PubMed ID: 21482999
[No Abstract] [Full Text] [Related]
58. Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors.
van Eijk M; Beijnen JH; Huitema ADR
Anticancer Drugs; 2023 Feb; 34(2):281-289. PubMed ID: 36730487
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials.
Vermunt M; Marchetti S; Beijnen J
Clin Pharmacol; 2021; 13():21-32. PubMed ID: 33536797
[TBL] [Abstract][Full Text] [Related]
60. [11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics.
van der Veldt AA; Lammertsma AA; Hendrikse NH
Clin Cancer Res; 2007 Dec; 13(24):7522; author reply 7522-3. PubMed ID: 18094438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
